Table 3 Maximum relaxation (E max ) of human bronchi and potency (pD 2 ) observed with chloroquine or phenanthroline in the presence or absence (control) of U73122 (1 μM, an inhibitor of PLCβ), iberiotoxin (0.1 μM, a selective inhibitor of BK Ca channels), thapsigargin (0.1 μM, an inhibitor of the sarcoplasmic reticulum Ca 2+ -ATPase), tetraethylammonium (1 mM, a non-selective potassium channels blocker), H89 (10 μM overnight, a PKA inhibitor), brefeldin A (20 μM overnight, an Epac inhibitor), indomethacin (1 µM, a cyclooxygenases inhibitor) and L-NAME (3 mM, a nitric oxide synthetase inhibitor)
From: The expression and relaxant effect of bitter taste receptors in human bronchi
| Â | Chloroquine | Phenanthroline | Â | ||
|---|---|---|---|---|---|
| Â | Emax(%) | pD2 | Emax(%) | pD2 | n |
Control | 93 ± 4 | 4.3 ± 0.2 | 96 ± 1 | 4.5 ± 0.1 | 6-10 |
U73122 | 96 ± 1 | 4.3 ±0.2 | 96 ± 1 | 4.5 ± 0.1 | 6 |
Iberiotoxin | 96 ± 3 | 4.2 ± 0.2 | 97 ± 0.1 | 4.3 ± 0.2 | 6 |
Thapsigargin | 99 ± 2 | 4.0 ± 0.1 | 94 ± 2 | 4.0 ± 0.2 | 6 |
Tetraethylammonium | 91 ± 3 | 4.2 ± 0.2 | 97 ± 1 | 4.5 ± 0.1 | 5-6 |
H89 | 98 ± 1 | 4.6 ± 0.1 | 99 ± 1 | 5.3 ± 0.5 | 5-6 |
Brefeldin A | 92 ± 2 | 4.6 ± 0.3 | 97 ± 1 | 4.5 ± 0.1 | 5-6 |
Indomethacin | 95 ± 2 | 4.3 ± 0.1 | 97 ± 1 | 4.2 ± 0.2 | 6-7 |
L-NAME | 94 ± 3 | 4.6 ± 0.2 | 98 ± 1 | 4.4 ± 0.1 | 5 |